Multiple Myeloma Clinical Trial

Clinical Trial Finder Multiple Myeloma Trials

A Study to Identify Barriers to Cellular Therapies for People With Plasma Cell Disorders

Summary

This is an observational study that will include both participants with relapsed/refractory Multiple Myeloma and their doctors. The purpose of this study is to gather information about the use of hematopoietic cell transplantation/HCT and B-cell maturation antigen /BCMS targeted chimeric antigen receptor/CAR autologous T-cell therapy.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Patient

Diagnosis of Multiple Myeloma after January 1, 2017.
Karnofsky Performance Status > 70%
≥ 2 lines of prior therapy
Anticipated to start new a line of therapy for RRMM within the next 12 months
Age 18-80 years of age.
English or Spanish speaking.
Willing to provide informed consent
Willing to perform study procedures.

Physician Investigator

Be a Co-Investigator
Agree to comply with study procedures

Exclusion Criteria:

Patient

Active CNS disease
Patients who already have a definitive plan are to be excluded

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit